DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...

Ankylosing spondylitis is a type of arthritis that inflames joints of the spine and leaves your back stiff and painful. If nonsteroidal anti-inflammatory drugs (NSAIDs) aren't enough to relieve your ...

Most people start a disease modifying antirheumatic drug (DMARD), such as methotrexate, soon after RA diagnosis. If you're still adjusting to a DMARD or want to better understand how it slows joint ...

Rheumatoid arthritis (RA) is an autoimmune condition in which the immune system attacks the lining of the joints. Traditional and biologic disease-modifying antirheumatic drugs (DMARDs) are two forms ...

The use of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for treating juvenile idiopathic arthritis (JIA) rose sharply from 2001 to 2022, while the use of ...

Since their first publication in 2010, the EULAR recommendations for the use of disease-modifying anti-rheumatic treatments (DMARDs) in people with RA have become a most important publication in the ...

After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...

Only slightly more than half of patients with newly diagnosed rheumatoid arthritis initiated therapy within 1 year. Objectives: To determine the rate of timely disease-modifying antirheumatic drug ...

Please provide your email address to receive an email when new articles are posted on . Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American ...